BioMarin Pharmaceutical (NASDAQ:BMRN) Trading 3.9% Higher on Analyst Upgrade

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares traded up 3.9% during trading on Tuesday after Truist Financial raised their price target on the stock from $80.00 to $100.00. Truist Financial currently has a buy rating on the stock. BioMarin Pharmaceutical traded as high as $61.40 and last traded at $61.5780. 557,089 shares changed hands during trading, a decline of 75% from the average session volume of 2,192,203 shares. The stock had previously closed at $59.28.

A number of other equities research analysts have also recently weighed in on BMRN. Raymond James Financial initiated coverage on BioMarin Pharmaceutical in a research note on Wednesday, September 3rd. They set an “outperform” rating and a $85.00 price target for the company. Morgan Stanley dropped their price objective on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating for the company in a research note on Tuesday, October 28th. Stifel Nicolaus restated a “hold” rating and set a $61.00 price objective (down from $73.00) on shares of BioMarin Pharmaceutical in a research report on Thursday, November 6th. Sanford C. Bernstein dropped their price target on BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating for the company in a research report on Monday, November 3rd. Finally, Leerink Partners lowered BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $82.00 to $60.00 in a research note on Wednesday, December 3rd. Sixteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, BioMarin Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $89.70.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Truist raised its price target on BMRN to $100 and initiated/maintained a “buy” view, citing large upside vs. current levels — a clear bullish signal that could support the stock over the medium term. Truist price target raise
• Positive Sentiment: BioMarin agreed to acquire Amicus Therapeutics for ~$4.8B, adding two growing rare-disease drugs and a late-stage pipeline asset — a transformational deal that expands revenues and R&D depth in rare-disease franchises. BioMarin to Buy Amicus for $4.8B
• Positive Sentiment: Analysts have grown more bullish on BioMarin after the Amicus deal, viewing the combination as value-accretive and supportive of future growth expectations. Positive analyst commentary can lift sentiment and long-term estimates. Analysts grow more bullish after Amicus acquisition
• Positive Sentiment: Industry write-ups and bullish commentaries (e.g., Seeking Alpha) highlight BioMarin’s rare-disease leadership and accelerating product sales (examples: Brineura growth), reinforcing the strategic rationale for the Amicus takeover. Seeking Alpha: Amicus buyout sparks enthusiasm
• Neutral Sentiment: HC Wainwright adjusted its price target modestly (to $60) and kept a neutral rating — a mixed signal that provides limited upside conviction relative to the more aggressive Truist target. HC Wainwright PT change
• Neutral Sentiment: Coverage pieces note conflicting analyst views across healthcare names, reflecting varying opinions on deal economics and integration risk for transactions like the Amicus acquisition. Mixed analyst commentary tends to increase short-term volatility. Analysts have conflicting sentiments
• Negative Sentiment: BioMarin discontinued development of BMN 349 (AATD therapy), a pipeline setback that reduces future upside from that program and may weigh on near-term sentiment given the loss of a potential long-term asset. BioMarin ends development of BMN 349

Institutional Investors Weigh In On BioMarin Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jump Financial LLC raised its position in BioMarin Pharmaceutical by 530.3% during the second quarter. Jump Financial LLC now owns 291,217 shares of the biotechnology company’s stock valued at $16,008,000 after purchasing an additional 245,017 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of BioMarin Pharmaceutical by 212.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company’s stock worth $112,607,000 after purchasing an additional 1,083,512 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of BioMarin Pharmaceutical by 90.7% in the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock worth $306,429,000 after purchasing an additional 2,654,768 shares in the last quarter. Covea Finance increased its position in shares of BioMarin Pharmaceutical by 27.3% during the 2nd quarter. Covea Finance now owns 135,300 shares of the biotechnology company’s stock valued at $7,437,000 after purchasing an additional 29,000 shares during the last quarter. Finally, 1832 Asset Management L.P. purchased a new position in shares of BioMarin Pharmaceutical during the 2nd quarter valued at about $1,431,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Trading Up 3.7%

The firm’s 50-day simple moving average is $53.81 and its 200-day simple moving average is $55.64. The firm has a market capitalization of $11.81 billion, a PE ratio of 23.15, a price-to-earnings-growth ratio of 1.02 and a beta of 0.30. The company has a quick ratio of 3.10, a current ratio of 4.83 and a debt-to-equity ratio of 0.10.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Monday, October 27th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.20). The firm had revenue of $776.13 million for the quarter, compared to the consensus estimate of $782.42 million. BioMarin Pharmaceutical had a net margin of 16.82% and a return on equity of 9.53%. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.91 earnings per share. BioMarin Pharmaceutical has set its FY 2025 guidance at 3.500-3.600 EPS. Equities analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.